This CME activity will review current investigations of the
myeloablative and nonmyeloablative preparative regimens used to
minimize complications and adverse events, to minimize disease relapse,
and to enhance long-term survival for patients with hematologic
malignancies undergoing HSCT.
|
Release date: April 2008
The content of this continuing medical education (CME) activity is derived from a symposium, “The Promise of Epigenetic Therapy,” presented at the 48th Annual Meeting of the American Society of Hematology.
Graft-versus-host disease (GvHD) is a common side effect of an allogeneic bone marrow or cord blood transplant. This program discusses the results of treating chronic GvHD with extracorporeal photopheresis.
RSS / Subscribe